Laimu Corporation
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 19, 2027The maintenance fee for Method for improving eye conditions (US 11,759,483) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same (US 11,911,417) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,973,858 | Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,911,417 | Nerve growth promoter and method for producing same, internal preparation, medium additive, cell dilution additive, medium, cell dilution, antioxidant and method for producing same, external preparation, and wound treatment agent and method for producing same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,345,675 | Compound, anti-allergy drug, and mediator release inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,179,414 | Method for producing protease degradation composition In force · From the USPTO record | In force | From the USPTO record | |
| US 11,246,849 | Nerve growth promoter In force · From the USPTO record | In force | From the USPTO record | |
| US 12,110,501 | Neurogenesis Stimulant, Internal Agent, Culture Medium Additive, Cell Diluent Additive, Culture Medium, and Cell Diluent In force · High confidence | In force | High confidence | |
| US 11,564,950 | Composition and method for producing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 11,759,483 | Method for improving eye conditions In force · From the USPTO record | In force | From the USPTO record | |
| US 12,622,933 | Method for Improving Eye Condition In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.